U.S. stock market midday update: GridAI Tech surges 11.41%, trading volume spikes, sector trend attracts market attention?

U.S. Stock Market Midday Update GridAI Tech, up 11.41%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Ultragenyx Pharmaceuticals down 44.63%. Based on recent key news: On December 29, Ultragenyx Pharmaceuticals announced that its investigational drug for treating hereditary bone disease failed to meet the primary efficacy endpoint in late-stage clinical trials. The drug did not significantly reduce the clinical fracture rate, leading to a sharp decline in stock price. Source: MT Newswires On December 29, the company plans to implement significant cost reductions in response to the trial results, further exacerbating market concerns about its financial condition. Source: SEC announcement On December 30, analysts downgraded their optimistic outlook for Ultragenyx, maintaining a buy rating but significantly lowering the price target. Source: MarketWatch. The biopharmaceutical industry has seen increased volatility recently and requires attention. Amgen down 0.72%. Based on recent news: On December 27, Amgen's third-quarter financial report showed total revenue increased from $9.18 billion in the second quarter to $9.56 billion, exceeding market expectations by $59 million. This strong financial data did not fully boost market confidence, leading to a slight decline in stock price. On December 11, Amgen's Uplizna drug received FDA approval for the treatment of chronic neuromuscular disease—generalized myasthenia gravis. Although this news improved the company's risk/reward profile, it did not significantly impact the stock price. No other significant news recently. The overall market is quite volatile and requires cautious observation. Praxis Precision Medicines up 13.66%. Based on recent key news: On December 29, Praxis Precision Medicines received FDA breakthrough therapy designation, driving the stock price up. This designation is based on positive data from the Essential3 project, with a new drug application expected to be submitted in early 2026. The stock price rose by about 17%. Source: RTT News On December 29, BTIG listed Praxis Precision Medicines as a preferred target for 2026 and raised the price target to $843, with the stock price rising over 2%. Source: RTT News On December 29, analysts maintained a buy rating, supporting the stock price increase. Jefferies and Oppenheimer both maintained buy ratings, with price targets of $450 and $750, respectively. Source: MarketBeat. The biopharmaceutical industry has performed strongly recently, with noticeable capital inflow Stocks Ranked Among the Top in Market Capitalization AbbVie rose by 0.51%. Based on recent news, On December 28, AbbVie's cash payout ratio was 61.8%, indicating strong fundamentals and a positive outlook for the next decade. Analysts believe the stock presents a strong buying opportunity until 2026, which boosted market confidence and drove the stock price up. On December 28, although AbbVie currently holds a "Moderate Buy" rating among analysts, top analysts believe there are five stocks that are more worthy of investment than AbbVie. This news may affect the sentiment of some investors, but overall it failed to prevent the stock price from rising. On December 28, market observers noted that AbbVie has performed exceptionally well over the past year, with no signs of slowing down. This further enhanced investor confidence in the company, driving the stock price up. The overall market performed well, with significant capital inflows